Arthrosamid: New Knee Injection to Know (2026)

Why Everyone Is Talking About Arthrosamid

If you have been searching for knee pain solutions recently, you have probably noticed a name popping up more and more: Arthrosamid. Google searches for this treatment have surged in 2026, and patient forums are buzzing with questions about it.

The interest is understandable. Arthrosamid promises something that no currently available knee injection can deliver: lasting pain relief from a single shot that does not wear off in six months.

But before you get too excited, there are some important realities to understand. Here is a clear, balanced look at what Arthrosamid actually is, what the evidence shows, and what US patients need to know right now.

What Is Arthrosamid?

Arthrosamid is a polyacrylamide hydrogel injection for knee osteoarthritis, developed by Contura International, a Danish medical device company. The product is made of 2.5% cross-linked polyacrylamide and 97.5% water.

What makes it different from every knee injection currently available in the United States is its mechanism:

Traditional HA injections (Synvisc, Euflexxa, Monovisc, etc.) add temporary lubrication to your joint fluid. Your body absorbs the gel over months, so you need repeat treatments.
Arthrosamid integrates into the synovial membrane (the lining of your joint) and creates a permanent, non-biodegradable cushion. It does not break down, so one injection could potentially last years.

This is not an incremental improvement over existing treatments. It is a fundamentally different approach to managing knee osteoarthritis pain.

Why the Sudden Surge of Interest?

Several factors are driving the breakout search interest in Arthrosamid:

1. Clinical Trial Results Are Encouraging

The MIVAC trial, published in Osteoarthritis and Cartilage in 2023, showed statistically significant pain reduction at 12 months compared to saline placebo. Follow-up data at 24 months showed sustained benefit without repeat injections. These results have been circulating in medical conferences and patient communities.

2. The Appeal of One-and-Done Treatment

For patients who currently get HA injections every 6 months (and deal with the scheduling, copays, and occasional insurance hassles), the idea of a single injection lasting 2 to 3 years or longer is enormously appealing. That message resonates deeply with the millions of Americans managing chronic knee OA.

3. Word of Mouth From International Patients

Arthrosamid has been available in Europe and the UK since receiving CE marking in 2017. Patients who have traveled abroad for the treatment have been sharing their experiences on social media, Reddit, and patient forums. Many of these reports are positive, which fuels interest among US patients.

4. Growing Frustration With Current Options

Many knee OA patients feel stuck between treatments that wear off quickly (cortisone, HA injections) and major surgery they are not ready for (knee replacement). Arthrosamid fills a gap in the treatment spectrum that patients have been asking about for years.

What the Evidence Actually Shows

Let us separate the facts from the hype.

What We Know

MIVAC trial results are real and published in a respected peer-reviewed journal
Pain reduction was statistically significant compared to placebo at 12 months
24-month data shows sustained benefit without retreatment
Safety profile appears favorable with adverse events similar to other knee injections
The SYMPHONY study is expanding the evidence base with larger patient numbers
CE marking in Europe means it has passed regulatory review there

What We Do Not Know

How long relief actually lasts beyond 2-3 years in most patients
Whether it works for severe arthritis (most studies focused on mild to moderate)
Long-term safety of a permanent implant in the knee over 10, 20, or 30 years
How it compares head-to-head with HA injections (no direct comparison trials)
Whether the hydrogel causes issues if knee replacement is needed later
How it performs in a large, diverse US population versus smaller European studies

The Honest Assessment

Arthrosamid’s early data is genuinely promising. It is not snake oil or marketing fluff. But “promising early data” is very different from “proven treatment.” Many therapies have looked great in early trials and then failed to deliver in larger, longer studies.

The US Availability Problem

Here is the part that frustrates many American patients: Arthrosamid is not available in the United States.

Current Status (March 2026)

Not FDA-approved for any indication in the US
Not available at any US clinic or hospital (except through clinical trials)
No HCPCS billing code exists, so insurance cannot cover it even theoretically
Contura International is pursuing FDA approval, but has not disclosed a specific timeline

When Might It Be Available?

Predicting FDA timelines is difficult, but here is a realistic framework:

Clinical trials must be completed and data submitted to the FDA
FDA review of a Pre-Market Approval (PMA) application typically takes 12 to 18 months
An advisory committee meeting may be required
Best-case scenario: Late 2027 or 2028 for potential approval
Realistic scenario: 2028 to 2029, possibly later if additional data is requested

There is no shortcut through this process, and there should not be. The FDA’s thorough review protects patients from treatments that seem promising but turn out to have hidden risks.

What Should US Patients Do Right Now?

If you have knee osteoarthritis and are interested in Arthrosamid, here is practical guidance:

1. Do Not Wait for Arthrosamid to Treat Your Pain

Knee OA is a progressive condition. Untreated pain leads to reduced activity, muscle loss, weight gain, and faster joint deterioration. Effective treatments are available right now.

2. Consider Proven Treatments Today

Physical therapy remains the foundation of knee OA management
Hyaluronic acid injections are FDA-approved, Medicare-covered, and effective for 6-12 months
Cortisone injections provide short-term relief for flare-ups
Weight management reduces load on arthritic joints
Bracing and activity modification help manage symptoms daily

3. Be Cautious About Medical Tourism

Some patients are traveling to Europe or the UK for Arthrosamid injections. If you consider this:

Verify the clinic’s credentials thoroughly
Understand that follow-up care will be managed by your US doctor, who may be unfamiliar with the product
Budget realistically: $3,000 to $5,000 for the injection plus travel and lodging
Inform your US physician so they can monitor you appropriately

4. Stay Informed

Sign up for updates on Arthrosamid FDA progress and clinical trial results. When new data is published, we will break it down in plain language.

What About Clinical Trials?

Some US patients may be able to access Arthrosamid through clinical trials. If you are interested:

Check ClinicalTrials.gov for active Arthrosamid studies
Ask your orthopedic doctor if they are aware of any enrollment opportunities
Understand that trial participation involves randomization (you may receive a placebo)
Clinical trials are free and include monitoring, but require commitment to the study protocol

Frequently Asked Questions

Is Arthrosamid FDA-approved?

No. As of March 2026, Arthrosamid is not FDA-approved for use in the United States. It is CE-marked in Europe and available in several countries outside the US.

How much does Arthrosamid cost?

At international clinics, Arthrosamid costs approximately $3,000 to $5,000 for the injection. This does not include travel, lodging, or follow-up care. It is not covered by any US insurance.

Is Arthrosamid permanent?

The polyacrylamide hydrogel is non-biodegradable, meaning your body does not break it down. It integrates into the synovial membrane and remains in place indefinitely. This is both its advantage (long-lasting) and a concern (cannot be easily removed).

Can Arthrosamid replace knee replacement surgery?

No. Arthrosamid is a pain management treatment, not a cure for osteoarthritis. It does not regenerate cartilage or repair structural damage. Patients with severe, end-stage arthritis may still need knee replacement. Arthrosamid may help delay surgery for patients with mild to moderate disease.

Is Arthrosamid better than Synvisc or other HA injections?

It is too early to make that comparison definitively. Arthrosamid may last longer, but HA injections have 25+ years of safety data, FDA approval, and insurance coverage. For a detailed breakdown, see our Arthrosamid vs. Hyaluronic Acid comparison.

Should I wait for Arthrosamid before getting knee injections?

No. Do not delay treatment for a product that may be years away from US availability. Treat your pain now with proven options, and consider Arthrosamid if and when it becomes available in the US.

The Bottom Line

Arthrosamid is a legitimate, innovative treatment that deserves the attention it is getting. The early clinical data is encouraging, and the concept of a single injection providing years of relief could genuinely change how we manage knee osteoarthritis.

But right now, in 2026, it is an emerging treatment that is not available to most American patients through normal channels. The FDA approval process will take time, and that is a good thing. Patients deserve thorough vetting of any treatment that will be permanently implanted in their bodies.

In the meantime, effective treatments exist today. Talk to your doctor about your options, manage your knee OA with proven therapies, and keep an eye on Arthrosamid’s progress.

Get Arthrosamid Updates Delivered to Your Inbox

Be the first to know about FDA developments, new clinical data, and US availability for Arthrosamid.

Join 10,000+ readers. No spam.